A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Sato
Takeo
T
Department of Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
Ozawa
Heita
H
Hatate
Kazuhiko
K
Onosato
Wataru
W
Naito
Masanori
M
Nakamura
Takatoshi
T
Ihara
Atsushi
A
Koizumi
Wasaburo
W
Hayakawa
Kazushige
K
Okayasu
Isao
I
Yamashita
Keishi
K
Watanabe
Masahiko
M
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D003967:Diarrhea / Q000209:etiology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D000077146:Irinotecan; D007564:Japan; D007970:Leukopenia / Q000209:etiology / Q000473:pathology; D008197:Lymph Node Excision / Q000379:methods; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009503:Neutropenia / Q000209:etiology / Q000473:pathology; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin